drugset / Trial / NCT03028987
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
Phase 4
Terminated
10 enrolled
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associated with the T-cell immune response.
Timeline
- Start
- 2014-11-19
- Primary completion
- 2015-11-18
- Completion
- 2015-11-18
Outcome
Outcome not reported
Stopped: “LAIV was no longer recommended by ACIP”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | — | Intranasal |
| Subject | Fluzone | Vaccine | — | — |